Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2024-09-19 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
现金分红管理制度（2024年9月）
Governance Information Classification · 95% confidence The document is titled '现金分红管理制度' which translates to 'Cash Dividend Management System' and details the company's policies, procedures, and mechanisms for cash dividend distribution. It references regulatory guidelines from the China Securities Regulatory Commission and the company's articles of association. The content is a detailed policy document on dividend distribution, shareholder returns, and related governance mechanisms. It is not an announcement of dividend amounts or payment dates, nor is it a brief summary or a report publication announcement. It is a governance-related document outlining internal rules and policies regarding dividends and shareholder returns. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 3231 characters, which is relatively short but contains substantive policy content rather than just an announcement or notice.
2024-09-19 Chinese
2024年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a resolution announcement for the 2024 third extraordinary shareholders' meeting of Shenzhen Haier Bioengineering Co., Ltd. It details the meeting date, voting methods, attendance, and the voting results on various proposals. It also includes legal opinions confirming the legality and validity of the meeting and resolutions. The document is a formal announcement of the voting results from a shareholders' meeting, not the meeting materials or the meeting itself. It does not contain financial statements or detailed financial analysis. The document length is 3687 characters, which is relatively short and consistent with a voting results announcement. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-09-19 Chinese
关于为控股子公司提供担保实施情况的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Shenzhen Haier Bioengineering Co., Ltd. regarding the provision of guarantees for its controlling subsidiaries. It lists multiple guarantee contracts with banks and financial institutions, specifying amounts, terms, and conditions. The document is an announcement about the company's guarantee activities to support subsidiaries' financing needs. It does not contain financial statements, audit opinions, or management discussions typical of annual or interim reports. It is not a call transcript, earnings release, or merger announcement. The content focuses on guarantees provided, which relates to financing activities. Therefore, the document fits best under the category of Capital/Financing Update (CAP), as it updates on the company's financing-related guarantee activities for subsidiaries.
2024-09-02 Chinese
关联方资金往来管理制度（2024年8月）
Governance Information Classification · 95% confidence The document is titled '关联方资金往来管理制度' which translates to 'Related Party Funds Management System' and is issued by Shenzhen Haier Bioengineering Co., Ltd. It outlines internal policies and procedures regarding the management of funds between the company and its controlling shareholders, actual controllers, and other related parties. The content includes regulatory references, definitions, management responsibilities, and audit requirements related to related party transactions and fund occupation. There is no indication that this is a financial report, audit report, or announcement of voting results. It is a governance-related internal policy document detailing rules and procedures for managing related party transactions and preventing misuse of company funds. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length (4602 characters) and detailed procedural content support this classification with high confidence.
2024-08-30 Chinese
半年报监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 14th meeting of the 9th Supervisory Board of Shenzhen Haiwang Bioengineering Co., Ltd. It includes details about the meeting date, attendance, and voting results. The key point is the approval of the 2024 semi-annual report and its summary by the Supervisory Board, confirming the report's compliance and accuracy. However, the document itself is not the semi-annual report but an announcement of the Supervisory Board's resolution regarding that report. The document is short (884 characters) and serves as a formal disclosure of meeting decisions rather than containing substantive financial data or the report itself. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-08-30 Chinese
关于减少注册资本及修订公司章程的公告
Share Issue/Capital Change Classification · 100% confidence The document is an announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding a reduction in registered capital and amendments to the company's articles of association. It details the decrease in share capital due to repurchase and cancellation of restricted shares, changes to the registered capital and total shares, and the need for shareholder approval and subsequent registration changes. The document is relatively short (1043 characters) and serves as a formal announcement of capital change and related corporate governance updates. It does not contain financial statements or detailed financial data, nor is it a report or presentation. This fits the definition of a Share Issue/Capital Change announcement (SHA).
2024-08-30 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.